The internationally renowned medical journal "The Lancet" recently published a research report stating that a German research team has developed a new drug "MEDIO382" that can treat type 2 diabetes. Glucagon-like peptide-1 and glucagon receptor dual agonists have been proven to improve blood sugar levels and effectively reduce weight. A German R&D team develops a potential new diabetes drug
This is the latest step in recent years for an international research team following two anti-hyperglycemic drugs such as "Oral SGLT-2 Inhibitor" and "Subcutaneous Injection of GLP-1 Incretin" , a hypoglycemic drug developed for subcutaneous injection, has the medical potential to treat type 2 diabetes and improve obesity.
The two hypoglycemic drugs "oral SGLT-2 inhibitors" and "subcutaneous injection of GLP-1 incretin" have shown good results in large multinational studies. They can not only lower blood sugar, but rarely cause The side effects of hypoglycemia include weight loss, cardiovascular disease morbidity and mortality. Diabetic patients who take hypoglycemic drugs will gain weight and experience three highs
Although diabetic patients take traditional oral hypoglycemic drugs or use insulin, although they can effectively lower blood sugar, they often have the side effect of weight gain. According to the results of a large diabetes study in the UK, patients who took insulin treatment for 12 years gained an average of 8 kilograms in weight. Another study also found that weight gain will have adverse effects on patients' blood pressure, blood lipids and blood sugar.
The American Diabetes Association's 2018 Patient Care Guidelines recommend that for diabetic patients suffering from cardiovascular disease whose blood sugar is still excessive after being given the diabetes drug Metformin, the above two new hypoglycemic drugs can be given priority.
Two new blood sugar-lowering drugs have remarkable therapeutic effects
These two new blood sugar-lowering drugs have been used by major domestic hospitals and have been included in health insurance benefits. Among them, "subcutaneous injection of GLP -1Encretin" can not only lower blood sugar, but also reduce the patient's appetite by affecting the central nervous system of the brain and inhibiting gastric emptying. After taking "oral SGLT-2 inhibitors", diabetic patients can eliminate about 70 grams of sugar in the urine every day, which is equivalent to 280 calories, which can effectively reduce the patient's excessive calorie intake. The follow-up development of new hypoglycemic drugs developed in Germany is worth observing
As mentioned earlier, the hypoglycemic drug MEDIO382 developed by a German research team has been confirmed in human experiments to significantly reduce the fasting blood sugar of diabetic patients. After treatment, blood sugar and glycated hemoglobin values ??also decreased, and hypoglycemia did not increase. What is more worth mentioning is that the patients who participated in the experiment lost weight and lowered their blood pressure.
Researchers said that the new drug under development may achieve clinically significant reductions in blood sugar and weight in obese or overweight patients with type 2 diabetes. The research and development of this new drug will still need to enter the stage of subsequent large-scale human trials.